Pfizer made the decision after a thorough review of data from the global, phase IIB, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, eight-arm, parallel-group study of vupanorsen in statin-treated participants with dyslipidemia. The study met its primary endpoint, achieving a statistically significant reduction in nonhigh density lipoprotein cholesterol (non-HDL-C) as well as statistically significant reductions in triglycerides and angiopoietinlike 3.

However, the magnitude of non-HDL-C and triglyceride reduction observed did not support continuing the program for cardiovascular risk reduction or severe hypertriglyceridemia. Vupanorsen was also associated with dose-dependent increases in liver fat, and higher doses were associated with elevations in the liver enzymes alanine aminotransferase and aspartate aminotransferase, according to a press release from Pfizer.

Pfizer will return the development rights of vupanorsen to Ionis, from which it licensed the investigational therapy in a worldwide exclusive agreement in November 2019.

Antisense oligonucleotide therapies get delivered across the blood-brain barrier
Researchers have demonstrated that heteroduplex oligonucleotide drugs conjugated with cholesterol efficiently cross the blood-brain barrier and can be...

Designer DNA therapies shown to effectively target cancer stem cells
Using an engineered DNA therapeutic agent to silence transcription factor genes reduced myeloma stem cell abundance and increased the survival of mice...

Ionis doses ALS patients with antisense medicine in clinical trial
Ionis Pharmaceuticals has dosed the first patients with ION541, an investigational antisense medicine developed to treat most forms of amyotrophic lateral...

Ionis' inhaled antisense drug shows promise as CF treatment
Ionis Pharmaceuticals has released positive data from a clinical trial evaluating IONIS-ENAC-2.5Rx, an investigational antisense medicine designed to...